Skip to Main Content

TIL

Animal-origin-free proteins for every step of TIL manufacturing.

From tumor tissue procurement to cryopreservation, recombinant albumin, IL-2, transferrin, and insulin-transferrin supplements replace human serum and plasma-derived albumin, lowering variability across a long expansion.

Where InVitria proteins fit in TIL Manufacturing

TIL therapy starts from a resected tumor and depends on its raw materials to keep scarce lymphocytes alive through transport, IL-2-driven outgrowth and rapid expansion. Human serum, plasma-derived albumin and transferrin, and bovine albumin bring donor and lot-to-lot variability into that chain, and plasma-derived albumin brings adventitious-agent risk into the drug product. Defined, animal-origin-free albumin, transferrin and insulin-transferrin supplements replace them step by step, and recombinant IL-2 replaces undefined IL-2 preparations.

Where our products fit

The TIL workflow, step by step.

Eight workflow steps in manufacturing order. Select any step to see the recommended products grouped by function, and why each one is used.

Tumor Tissue Procurement & Starting Material

Procure a resected tumor specimen as the source of tumor-infiltrating lymphocytes, and protect the tissue in transport media with defined, animal-origin-free albumin.

Overview

Tumor tissue procurement is the first step in tumor-infiltrating lymphocyte (TIL) therapy. Unlike blood-derived cell therapies, TIL therapy starts from solid tumor tissue: a tumor lesion is surgically resected from the patient, typically at least 1.5 cm or pooled from several biopsies. Melanoma is the most established indication, with lung, renal, cervical, and other solid tumors under study.

The resected specimen is placed in biopreservation or transport media and shipped cold, usually at 2 to 8 degrees Celsius, by overnight transport to the manufacturing facility. The interval and conditions between resection and processing affect the viability of the lymphocytes held within the tissue.

Protecting the tissue and its resident cells during transport supports recovery of viable TILs. A defined, animal-origin-free stabilizing protein in the transport medium avoids introducing serum- or animal-derived material at the start.

Functions

Starting Material Stabilization

TIL therapy starts from a resected tumor specimen that must be transported cold to the manufacturing site before processing. The lymphocytes held within the tissue are sensitive to the interval and conditions of transport, and their viability affects the success of the outgrowth that follows. A stabilizing protein in the transport or biopreservation medium supports cell health through shipping and hold.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Serum or plasma-derived albumin in tissue transport and biopreservation media.

Tumor Processing & TIL Isolation

Process the tumor into fragments or a cell suspension to release tumor-infiltrating lymphocytes, with defined, animal-origin-free albumin protecting the cells.

Overview

Tumor processing and TIL isolation prepares the tissue so that lymphocytes can be recovered and cultured. The tumor is dissected into small fragments of roughly 1 to 3 cubic millimeters. The fragments are either cultured directly, allowing TILs to emigrate out, or digested mechanically and enzymatically to release a cell suspension.

Enzymatic and mechanical digestion release cells quickly but can damage TILs, so the gentler fragment method is widely used. The digestion enzymes, such as collagenase, are supplied separately and are not InVitria products. Processing exposes the released cells to mechanical stress and buffer exchange.

A defined, animal-origin-free recombinant albumin protects the released cells through processing and washing while keeping the workflow free of serum-derived material.

Functions

Cell Protection & Stabilization

During processing, the tumor is fragmented or digested, which exposes the resident lymphocytes to mechanical and, where used, enzymatic stress before they enter culture. Albumin supports viability by transporting fatty acids and binding reactive species, buffering the released cells against handling and oxidative stress and helping limit damage as TILs are recovered from the tissue.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Serum or bovine serum albumin (BSA) in tumor processing and wash buffers.

Initial TIL Culture & Outgrowth

Culture the tumor fragments in high-dose IL-2 so tumor-infiltrating lymphocytes grow out and expand, on a defined, animal-origin-free base. (pre-REP)

Overview

Initial TIL culture and outgrowth, the pre-rapid-expansion protocol (pre-REP), is where the lymphocytes grow out of the tumor. The fragments or released cells are cultured in high-dose interleukin-2 (IL-2), commonly 600 to 6000 IU/ml, for roughly two to five weeks. TILs emigrate from the tissue and expand in response to IL-2, while tumor cells die off under lymphocyte culture conditions.

IL-2 is the driver of this phase; the outgrowth depends on a sustained, high-dose IL-2 supply replenished every few days. Some protocols add IL-15 and IL-21 to enhance outgrowth; these are not InVitria products. The cells are supported by a defined protein and metabolic base in place of human serum.

A defined, animal-origin-free IL-2 and protein base supports consistent outgrowth while keeping the long culture free of serum- and animal-derived material.

Functions

Cytokine Signaling

Outgrowth depends entirely on interleukin-2 (IL-2). TILs emigrate from the tumor fragments and proliferate in response to high-dose IL-2 signaling through the IL-2 receptor, while the cytokine is replenished every few days across a multi-week culture. A consistent, defined, high-activity IL-2 source is the central soluble factor of the pre-REP outgrowth phase.

Recommendation
OptiLeukin™ 2

Recombinant human interleukin-2 from a non-bacterial expression system for T-cell, Treg, TIL, NK, and γδ T-cell expansion, from research to cGMP manufacturing.

Commonly replaces
Non-recombinant or undefined IL-2 preparations in TIL culture.

Carrier & Protection

Through the multi-week outgrowth, albumin is the primary protein carrier supporting the emerging TILs. It binds and transports fatty acids, lipids, and metal ions, contributes antioxidant capacity, and buffers cells against handling stress as they egress from the tissue and begin to proliferate.

Recommendation
Cellastim® S

Cell culture recombinant albumin to enhance proliferation in serum free and chemically defined cell culture. Lyophilized.

Commonly replaces
Human serum, human serum albumin (HSA), or bovine serum albumin (BSA) in TIL media.

Serum-Free Environment Support

TIL outgrowth media are moving from human serum toward defined, serum-free formulations built on a metabolic base, insulin for metabolism, transferrin for iron, and selenium for oxidative balance. A blend supplies these in one addition, supporting the emerging TILs while IL-2 drives outgrowth separately.

Recommendation
ITSE+A Animal-Free®

Five-component 100x supplement of recombinant insulin, recombinant human transferrin, selenium, ethanolamine, and recombinant human albumin for serum-free cell culture.

Commonly replaces
Human serum or FBS in TIL outgrowth media.

TIL Activation & Selection

Optionally select tumor-reactive TIL cultures and activate them through CD3 to enter rapid expansion, with IL-2 and defined albumin supporting the cells.

Overview

TIL activation and selection bridges outgrowth and rapid expansion. In the selected-TIL approach, individual TIL micro-cultures are tested for tumor reactivity, for example by interferon-gamma response against autologous or HLA-matched tumor, and the reactive cultures are carried forward. In the bulk or young-TIL approach, this selection is skipped to save time.

The selected or bulk TILs are then activated through the T cell receptor with anti-CD3 (OKT3) to prime them for the rapid expansion that follows. The reactivity assays and anti-CD3 reagents are supplied separately and are not InVitria products. IL-2 is maintained throughout to keep the cells viable and proliferating.

A defined, animal-origin-free IL-2 and protein base supports the cells through selection and activation, while keeping the process free of serum- and animal-derived material.

Functions

Cytokine Signaling

Through selection and activation, TILs remain dependent on IL-2 to stay viable and continue proliferating. As the cells are tested, carried forward, and primed through CD3 for rapid expansion, a sustained IL-2 signal holds the culture and prevents loss of the reactive TILs before the expansion phase.

Recommendation
OptiLeukin™ 2

Recombinant human interleukin-2 from a non-bacterial expression system for T-cell, Treg, TIL, NK, and γδ T-cell expansion, from research to cGMP manufacturing.

Commonly replaces
Non-recombinant or undefined IL-2 preparations in TIL culture.

Carrier & Protection

During selection and activation, albumin continues to support TIL viability as the primary protein carrier, binding and transporting fatty acids, lipids, and metal ions, contributing antioxidant capacity, and buffering cells against handling stress as they are assayed and primed for expansion.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Serum, human serum albumin (HSA), or bovine serum albumin (BSA) in TIL media.

Rapid Expansion Protocol

Expand TILs to billions of cells with high-dose IL-2, anti-CD3, and feeder cells, on a defined, animal-origin-free base. (REP)

Overview

The rapid expansion protocol (REP) grows the TILs to the therapeutic dose, often tens of billions of cells, over roughly two weeks. The cells are stimulated with high-dose IL-2 and anti-CD3 (OKT3) in the presence of irradiated allogeneic PBMC feeder cells, classically at a 1:200 TIL-to-feeder ratio, or with artificial antigen-presenting cells as an alternative.

The anti-CD3 reagent and the feeder cells or artificial APCs are supplied separately and are not InVitria products. IL-2 remains the central soluble driver, and the intense proliferation demands iron, carrier protein, and metabolic support. REP is run in gas-permeable flasks or bioreactors where the cells experience handling and shear.

A defined, animal-origin-free expansion strategy supports consistent high-fold expansion while keeping the process free of serum- and animal-derived material.

The REP uses anti-CD3 (OKT3) activation with irradiated allogeneic feeder cells and high-dose IL-2 to expand TILs to therapeutic numbers over ~14 days.

Functions

Cytokine Signaling

The rapid expansion protocol depends on sustained high-dose IL-2. Alongside anti-CD3 and feeder stimulation, IL-2 drives the intense proliferation that takes TILs to the therapeutic dose, signaling through the IL-2 receptor across roughly two weeks of culture. A consistent, defined, high-activity IL-2 source is the central soluble factor of the REP.

Recommendation
OptiLeukin™ 2

Recombinant human interleukin-2 from a non-bacterial expression system for T-cell, Treg, TIL, NK, and γδ T-cell expansion, from research to cGMP manufacturing.

Commonly replaces
Non-recombinant or undefined IL-2 preparations in TIL expansion.

Iron Transport

The intense proliferation of the REP sharply raises the TILs’ demand for iron for metabolism and DNA synthesis. In serum-free and defined media, transferrin delivers iron in a controlled, protein-bound form through the transferrin receptor, supporting high-fold expansion while limiting the oxidative stress associated with free iron. Transferrin is a core component of defined T cell media.

Recommendation
Optiferrin®

Recombinant human transferrin, lyophilized, for iron delivery in serum-free and chemically defined media.

Commonly replaces
Serum- or plasma-derived transferrin, and serum as an iron source.

Carrier & Protection

Albumin is the primary protein carrier in defined T cell media. It binds and transports fatty acids, lipids, and metal ions, contributes antioxidant capacity, and buffers cells against the handling and shear of high-density culture in gas-permeable flasks and bioreactors. Through the REP, this carrier and protective role supports TIL viability and consistent high-fold expansion.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Serum, human serum albumin (HSA), or bovine serum albumin (BSA) in expansion media.

Serum-Free Environment Support

Serum-free rapid expansion depends on a defined metabolic base, insulin for metabolism, transferrin for iron, and selenium for oxidative balance, in place of human serum. A blend supplies these in one addition, supporting the intense proliferation of the REP while IL-2 and stimulation drive expansion separately.

Recommendation
ITSE+A Animal-Free®

Five-component 100x supplement of recombinant insulin, recombinant human transferrin, selenium, ethanolamine, and recombinant human albumin for serum-free cell culture.

Commonly replaces
Human serum or FBS in TIL rapid expansion media.

Harvest, Wash & Concentration

Collect and concentrate the rapidly expanded TILs, separating them from feeder debris, with defined, animal-origin-free albumin protecting cells.

Overview

Harvest and concentration collects the expanded TILs from the rapid expansion culture and brings them to the density needed for downstream processing. The cells are pooled from the culture vessels and concentrated by centrifugation or filtration, with volume reduction to remove spent media and residual feeder-cell debris.

Harvest and volume reduction expose the large cell mass to mechanical and shear stress. Buffers used at harvest commonly contain albumin to protect cells and limit loss during these steps.

A defined, animal-origin-free recombinant albumin protects TILs through harvest and concentration while avoiding animal-derived residuals ahead of washing and formulation.

Harvest, wash, and buffer exchange are performed as one volume-reduction operation (counterflow centrifugation), replacing the separate wash step.

Functions

Cell Protection & Stabilization

During harvest, the large expanded TIL mass is pooled and concentrated by centrifugation or filtration, which exposes the cells to mechanical and shear stress and the risk of loss to surfaces. Albumin protects cells by transporting fatty acids and binding reactive species, buffering them against handling and shear through volume reduction and concentration.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Serum or bovine serum albumin (BSA) in harvest buffers.

Final Formulation & Fill Prep

Formulate the TILs into their final infusion or cryopreservation matrix with defined, animal-origin-free recombinant albumin, a drug-product excipient.

Overview

Final formulation and fill prep brings the TIL product to its finished form. The washed cells are suspended in the matrix they will be stored and administered in, then filled into the primary container, a blood transport and infusion bag or a cryopreservation bag. The product is a live TIL suspension for intravenous infusion.

Albumin is a standard excipient in these matrices. It stabilizes the cells through formulation and, for cryopreserved products, into freezing. Because this is the drug product, excipient safety matters: plasma-derived albumin carries adventitious-agent risk that a recombinant source removes.

A defined, animal-origin-free recombinant albumin stabilizes the formulated product while keeping the final matrix free of human- and animal-derived material as it goes to fill.

Functions

Formulation Stabilization

In final formulation, the cells are suspended in the matrix they will be stored and administered in, commonly an electrolyte solution with albumin and, for cryopreserved products, a cryoprotectant. Albumin is a standard excipient in this matrix. It stabilizes cells, buffers them against the osmotic and handling stress of formulation, and limits adsorption to the container. As a drug-product excipient, its quality and safety profile carry into the final product.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Plasma-derived human serum albumin (HSA) used as a formulation excipient.

Cryopreservation & Storage

Freeze and store the TIL product, with defined, animal-origin-free albumin supporting cell viability and function through freeze-thaw.

Overview

Cryopreservation and storage freezes and banks the finished TIL product. In current (cryopreserved) processes, the formulated cells are cooled in a controlled-rate freezer and held in cryogenic storage, then thawed at the clinical site before infusion. Cryopreservation decouples manufacturing from the patient’s treatment schedule; some earlier processes infused fresh product instead.

Freeze-thaw exposes cells to ice formation and osmotic stress, and TILs must retain viability and anti-tumor function after thaw. Cryopreservation matrices pair a penetrating cryoprotectant such as DMSO with a protein stabilizer; albumin is the standard stabilizer, buffering cells through freezing.

A defined, animal-origin-free recombinant albumin supports cryostability and recovery while keeping the frozen drug product free of human- and animal-derived material.

Functions

Freeze-Thaw Stabilization

Cryopreservation exposes cells to ice crystal formation, osmotic shifts, and membrane stress during freezing and thawing, and TILs must retain viability and anti-tumor function on thaw. Cryopreservation matrices pair a penetrating cryoprotectant such as DMSO with a protein stabilizer. Albumin acts as that stabilizer, a non-penetrating component that buffers membranes against osmotic and oxidative stress and supports viability and recovery after thaw.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Plasma-derived human serum albumin (HSA) used as a cryopreservation stabilizer.